Communications publiées lors de congrès ou colloques nationaux et internationaux (4)
1.
Ando, K., Pregoni, G., Verheijen, J., Vergara Panos, C., De Decker, R., Mansour, S., Yilmaz, Z., Suain, V., Dauphinot, L., Fontaine, G., Leroy, K., Duyckaerts, C., Sleegers, K., Potier, M.-C., & Brion, J. P. (2018). PICALM susceptible loci and the levels of its mRNA and protein expression. 2nd EUROtau meeting abstract book 2nd EUROtau meeting(2: 26-27 April 2018: Lille, France)2.
Houben, S., Audouard, E., Masaracchia, C., Yilmaz, Z., Suain, V., Authelet, M., De Decker, R., Buée, L., Boom, A., Leroy, K., Ando, K., & Brion, J. P. (2016). Stereotaxic injection of fibrillar PHF from Alzheimer brain induces propagation of argyrophilic grains constituted of murine tau in mouse brains. Front. Aging Neurosci.. Vol. 40 6th Belgian Brain Congress.(6: 2016-10-08: Mons, Belgium). doi:10.3389/conf.fnagi.2016.03.000403.
Vergara Panos, C., Houben, S., Vanden Dries, V., Yilmaz, Z., Suain, V., De Decker, R., Duyckaerts, C., Boom, A., Leroy, K., Ando, K., & Brion, J. P. (2016). PHF-tau propagation in the presence of Amyloid ß pathology. Front. Aging Neurosci. (p. 219818) 6TH BELGIAN BRAIN CONGRESS(6: 2016-10-08: Mons, Belgium). doi:10.3389/conf.fnagi.2016.03.000174.
Ando, K., Brion, J. P., Stygelbout, V., Tomimura, K., Suain, V., Authelet, M., De Decker, R., Chanut, A., Belkouch, M., Lacor, P., Lavaur, J., Sazdovitch, V., Rogaeva, E., Potier, M.-C., & Duyckaerts, C. (2014). ALZHEIMER RISK FACTOR PICALM IS INVOLVED IN TAU PATHOLOGY IN ALZHEIMER AND OTHER TAUOPATHIES. Alzheimer's & Dementia: The Journal of the Alzheimer's Association. Vol. 10 (4 ed., p. P297) AAIC 2014(2014-07-12 to 2014-07-17: Copenhagen, Danmark). Participations à des congrès et colloques internationaux (35)
1.
De Fisenne, M.-A., Yilmaz, Z., De Decker, R., Suain, V., Mansour, S., Buée, L., Ando, K., Brion, J. P., & Leroy, K. (2022). Alzheimer PHF-tau do not spread tau pathology to the brain via the retinotectal pathway after intraocular injection in mouse models. Paper session presented at International conference on Alzheimer and Parkinson's diseases (15-22 March 2022: Barcelona).2.
De Fisenne, M.-A., Houben, S., Ando, K., Vanden Dries, V., Poncelet, L., Yilmaz, Z., Mansour, S., De Decker, R., Brion, J. P., & Leroy, K. (2022). Intravenous injection of PHF-Tau proteins from Alzheimer Brain exacerbates neuroinflammation, Amyloid beta, and tau pathologies in 5XFAD transgenic mice.. Vol. 145 (p. 411) Abstract session presented at International conference on Alzheimer and Parkinson's diseases(15-20 Mars 2022: Barcelona).3.
De Fisenne, M.-A., Yilmaz, Z., De Decker, R., Suain, V., Mansour, S., Buée, L., Ando, K., Brion, J. P., & Leroy, K. (2022). Alzheimer PHF-tau do not spread tau pathology to the brain via the retinotectal pathway after intraocular injection in mouse models.. Vol. 130 (p. 176) Abstract session presented at International conference on Alzheimer and Parkinson’s diseases(15-22 mars 2022: Barcelona).4.
De Fisenne, M.-A., Yilmaz, Z., De Decker, R., Suain, V., Mansour, S., Buée, L., Ando, K., Brion, J. P., & Leroy, K. (2021). Alzheimer PHF-tau do not spread tau pathology to the brain via the retinotectal pathway after intraocular injection in mouse models. (p. 54) Abstract session presented at Oral presentation to the Third Eurotau meeting(October 25-26,: Lille, France).5.
De Fisenne, M.-A., Yilmaz, Z., De Decker, R., Suain, V., Mansour, S., Buée, L., Ando, K., Brion, J. P., & Leroy, K. (2021). Alzheimer PHF-tau do not spread tau pathology to the brain via the retinotectal pathway after intraocular injection in mouse models. (p. 99) Abstract session presented at New Horizons in Alzheimer’s Disease(October 27-28, 2021: Leuven, Belgium).6.
Ando, K., De Decker, R., Vergara Panos, C., Yilmaz, Z., Mansour, S., Suain, V., Slegers, K., De Fisenne, M.-A., Houben, S., Potier, M.-C., Duyckaerts, C., Watanabe, T., Buée, L., Leroy, K., & Brion, J. P. (2021). Picalm reduction exacerbates tau pathology in a murine tauopathy model. (p. 77, Poster 04) Abstract session presented at New Horizons in Alzheimer’s Disease(October 27-28, 2021: Leuven, Belgium).7.
Kosa, A.-C., Ando, K., Lasri, H., Yilmaz, Z., Doeraene, E., López Gutiérrez, L., De Decker, R., Mansour, S., Suain, V., & Brion, J. P. (2021). Deletion of murine APP accelerates cognitive deficits in a murine model of amyloid and tau pathologies. (p. 129) Abstract session presented at New Horizons in Alzheimer’s Disease(October 27-28, 2021: Leuven, Belgium.).8.
Ando, K., Ndjim, M., Turbant, S., Fontaine, G., Pregoni, G., Dauphinot, L., Suain, V., Mansour, S., Authelet, M., De Decker, R., Delatour, B., Brain Bank NeuroCEB Neuropathology Network,, Duyckaerts, C., Leroy, K., Potier, M.-C., & Brion, J. P. (2021). The lipid phosphatase Synaptojanin 1 undergoes a significant alteration in expression and solubility and is associated with brain lesions in Alzheimer’s disease. (p. 60) Abstract session presented at Poster presentation to the Third Eurotau meeting(October 25-26, 2021: Lille, France).